RSS

TX200

TxCell has exercised its exclusive option to in-license the intellectual property rights of one of its academic partners, the University of British Columbia (UBC), onto its HLA-A2 CAR-Treg programme. Read more

Technology

A Master Service Agreement has been entered by TxCell and Lonza Pharma & Biotech for the manufacture of a CAR-Treg cellular product (TX200), which is in development for the prevention of chronic rejection after organ transplantation. Read more

News